What GLP-1 Medications Actually Cost in 2026: Cash Pay, Compounded, and Sourcing Safely

A GLP-1 prescription can come with a sticker price that stops you cold — and the internet is full of cheaper-looking alternatives, not all of which are safe or legal. The good news in 2026 is that the manufacturers' own cash prices have come down and the first pills are here. The key is knowing which paths are legitimate.

Manufacturer cash-pay: the safest discount

Both major manufacturers now sell their brand-name GLP-1s directly to people paying cash, at prices well below the old list prices. This is the same FDA-approved medication you would get with insurance — just a different way to pay.

The practical takeaways: the lowest advertised numbers are often short-term introductory offers, and the tirzepatide vial price depends on refilling on time. Read the program's terms before you commit, and set a reminder for any refill window.

The new option in 2026: the pill

For years GLP-1s meant a weekly injection. That changed in 2026 with two oral options:

• Oral semaglutide (oral Wegovy) — approved in late 2025 as the first GLP-1 pill cleared for weight management, and on the US market in early 2026. Cash-pay starts near $149/month at the lowest dose, stepping up to roughly $199 and $299/month at higher doses. In its trial, completers lost about 16.6% of body weight over 64 weeks. It must be taken on an empty stomach with a small sip of water and about a 30-minute wait before eating, drinking, or other medicines.
• Orforglipron (Foundayo) — approved April 1, 2026 as the first oral small-molecule GLP-1 pill, with no food, water, or timing restrictions. Cash-pay also starts near $149/month at the lowest dose. It is a different molecule from tirzepatide; there is no oral form of tirzepatide itself.

Pills are not automatically cheaper than the discounted injectables at higher doses, and whether a pill or an injection is right for you is a clinical decision. Talk it through with your clinician.

Compounded GLP-1s: mostly a closed door now

During the shortages, compounding pharmacies legally made large quantities of semaglutide and tirzepatide, often at lower prices. That window has largely closed, and it is worth understanding why so you are not relying on a source that is no longer permitted.

The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. Once a shortage ends, the broad allowance for compounding it winds down — and those wind-down deadlines passed during 2025. In April 2026, the FDA went further and proposed permanently barring semaglutide, tirzepatide, and liraglutide from the list of bulk substances that large “503B” outsourcing facilities may compound; the public comment period runs through late June 2026, and the proposal was not yet final as of this writing.

A compounding pharmacy may still prepare a GLP-1 for a genuine, individualized clinical need — for example, a documented allergy to an inactive ingredient in the commercial product — but not as what is essentially a copy of the approved drug for cost reasons. If a seller offers “compounded semaglutide” cheaply to anyone, that is a sign to pause and verify.

Research peptides and gray-market sellers: what to look for

A growing online market sells semaglutide or tirzepatide as “research peptides,” often labeled research use only or not for human consumption. Those labels do not make a product safe or legal to use — and the FDA has flagged serious risks with these unapproved sources: contamination, inconsistent or counterfeit active ingredients, and dosing errors (especially from drawing doses out of multi-dose vials). As of mid-2025 the FDA had received about 1,150 adverse-event reports tied to compounded semaglutide and tirzepatide, including hospitalizations, and notes such events are likely underreported. In early 2026 it sent 30 warning letters to telehealth sellers marketing these products (made public March 3, 2026).

If you are weighing a low-cost online source, a few questions help you tell a legitimate pharmacy from a risky one:

• Is it a licensed US pharmacy that requires a valid prescription and a real clinical evaluation — not just a checkout form?
• Does it sell an FDA-approved product (brand-name semaglutide or tirzepatide), rather than a “research” peptide?
• Will it tell you where the medication is made and let a pharmacist answer questions?
• Does the price seem far below the manufacturer cash-pay prices above? Unusually low pricing is a reason to verify, not to rush.

When in doubt, the manufacturer cash-pay programs and a licensed pharmacy are the routes with the clearest safety and legal footing.

If cost is the barrier and you have a medical condition

Before paying cash, it is worth checking whether the medication could be covered. GLP-1s are covered far more widely for conditions like type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea than for weight management alone. If one of those applies to you, the medication may be a covered benefit under a different indication — a clinical question for your prescriber, based on your actual health.

If the medication is covered but your plan requires prior authorization, or it was denied, those have their own playbooks — see GLP-1 coverage and prior authorization and how to appeal a denial. And if out-of-pocket cost is the only barrier, the manufacturers run income-based patient assistance programs — verify eligibility directly with the manufacturer.